MetaCap

Trupanion (TRUP) vs YD Bio (YDES)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.

Summary

Trupanion (TRUP) has outperformed YD Bio (YDES) over the past year, losing 41.8% versus a loss of 67.3%. Trupanion is the larger company by market cap ($1.08 billion vs $408.0 million), about 2.6 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

TRUP-41.77%YDES-67.33%
+17%-39%-94%
Oct 7, 20251 yearOct 7, 2026
TRUP-46.87%YDES-52.96%
+93%+0%-93%
Aug 25, 20255 yearsOct 5, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

TRUP versus YDES key metrics
MetricTRUPYDES
Share price$24.73$5.76
Market cap$1.08B$407.99M
1-day change+0.39%-2.04%
YTD return-34.09%-51.76%
1-year return-41.77%-67.33%
5-year return-72.98%—
P/E ratio (TTM)46.65—
Forward P/E5.80—
EPS (TTM)$0.53$-0.04
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
52-week high$46.98$22.00
52-week low$21.16$1.70
Distance from 52-week high-47.37%-73.82%
Analyst consensusbuy—
Avg. price target upside+38.52%—
Average volume470.46K283.39K
Shares outstanding43.62M70.83M
Employees1,12113
SectorHealth CareHealth Care
IndustryMedical SpecialitiesMedical Specialities

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • Trupanion is about 2.6 times larger than YD Bio by market value ($1.08B vs $407.99M).
  • TRUP has outperformed YDES by 25.6 percentage points over the past year.

About Trupanion

TRUP stock →

Trupanion, Inc., together with its subsidiaries, provides medical insurance for cats and dogs on subscription basis in the United States, Canada, and Continental Europe. The company operates in two segments, Subscription Business and Other Business.

Health Care · Medical Specialities · 1,121 employees

About YD Bio

YDES stock →

YD Bio Limited, a biopharmaceutical company, focuses on regulated diagnostics, life science clinical services, and healthcare product commercialization in the United States and Taiwan. The company offers eye disease treatment products, 3D LensMate Artificial Tears, a natural tear-mimicking lubricant that moisturizes the eyes and relieves dry eye symptoms; 3D LensMate Eye Drops, an ophthalmic solution to alleviate symptoms of dry eye syndrome, including irritation, foreign body sensation, and eye fatigue; and LSC Eye Drug/Injection, an injectable ophthalmic drug is being developed for the treatment of various retinal and macular disorders, such as age-related macular degeneration, macular edema, choroidal and subretinal neovascularization, and neovascular glaucoma.

Health Care · Medical Specialities · 13 employees

TRUP vs YDES FAQ

Which is bigger, Trupanion or YD Bio?

Trupanion (TRUP) is larger, with a market capitalization of $1.08B compared with $407.99M for YD Bio (YDES).

Which stock has performed better over the past year, TRUP or YDES?

TRUP returned -41.77% over the past 12 months, compared with -67.33% for YDES (price return, excluding dividends). Past performance does not predict future results.

Are Trupanion and YD Bio in the same industry?

Yes. Both are classified in the Medical Specialities industry within the Health Care sector.

More comparisons